A statement released earlier today by HSBC about Gerresheimer (ETR:GXI) bumps the target price to 72.00EUR

Stating a potential upside of 0.01%, HSBC upped the price target of Gerresheimer (ETR:GXI) to 72.00EUR

On Monday October 10, 2016, Hauck & Aufhäuser Privatbankiers KGaA released a statement on Gerresheimer (ETR:GXI) upped the target price from 0.00EUR to 80.00EUR that suggested an upside of 0.09%.

Having a price of 71.20EUR, Gerresheimer (ETR:GXI) traded 0.00% even on the day. The last closing price is up 0.00% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Gerresheimer has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Volume of trade held steady, with 0 shares of GXI changing hands on par with the typical 0

Performance Chart

With a market capitalization of 0 EUR, Gerresheimer has 52 week low of 0.00EUR and a 52 week high of 0.00EUR .

Brief Synopsis On Gerresheimer (ETR:GXI)

Gerresheimer AG is a Germany-based company that operates in the pharmaceuticals and health care industry. It is structured in three business segments: Plastic and Devices, Primary Packaging Glass and Life Science Research. The Company produces pharmaceutical packaging products, as well as drug-delivery systems made out of glass and plastics or a combination of both. Its product portfolio includes insulin pens, inhalers, pre-fillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products. The Company operates approximately 40 production facilities in Europe, North America, South America and Asia.